App-Quantinova.ai

Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM) A multicenter analysis.

Aurelius Gabriel Omlin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Radium-223 Dichloride

Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Sunil Parimi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Re-treatment with radium-223: An international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases.

A. Oliver Sartor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Enzalutamide

Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

Michael J. Morris - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Radium-223 Dichloride

A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.

Joyce M. van Dodewaard-de Jong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rhenium-188-HEDP

The MITO8 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGOG, ENGOT, and GCIG.

Sandro Pignata - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin Hydrochloride

Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients.

Victor Rodriguez Freixinos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis.

Kyle Strickland - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tumor-infiltrating CD204+ M2 macrophages compared to T cells as a prognosticator for patients with uterine cervical adenocarcinoma.

Asuka Kawachi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: Safety and clinical activity.

Mary L. Disis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Avelumab

Preliminary results from the first in human study of activin-A inhibitor, STM434, in patients with granulosa cell ovarian cancer and other advanced solid tumors.

David Michael Hyman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

STM 434

A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

Erika Paige Hamilton - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Olaparib

Pembrolizumab in advanced endometrial cancer: preliminary results from the phase 1b KEYNOTE-028 study.

Patrick Alexander Ott - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Altered immune environment in Lynch syndrome-related endometrial cancer: Implications for immunotherapy?

Janelle B. Pakish - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of body mass index on surgical costs and morbidity for women with endometrial carcinoma/hyperplasia.

Rudy Sam Suidan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical significance of homologous recombination deficiency (HRD) score testing in endometrial cancer patients.

Jean M. Hansen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Olaparib

Mutational landscape of uterine and ovarian carcinosarcomas.

Gulden Menderes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Chemotherapy and radiotherapy in early stage uterine papillary serous and clear cell carcinoma: A National Cancer Data Base study.

Julian C. Hong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).

Alessandro Santin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial.

Jean Bourhis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Filters

41730 Abstracts